M. Lange

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst et al. · New England Journal of Medicine · 1999 · 2.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial

Daniel J. Lovell, Edward H. Giannini, Andreas Reiff et al. · Arthritis & Rheumatism · 2003 · 256 citations

Medicine, Pediatrics, Pharmacotherapy +14

ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.

Anke M. van Gestel, Jennifer J. Anderson, Piet L. C. M. van Riel et al. · PubMed · 1999 · 250 citations

Medicine, Clinical Sciences, Internal Medicine +17

Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

David T. Felson, Jennifer J. Anderson, M. Lange et al. · Arthritis & Rheumatism · 1998 · 192 citations

Medicine, Biostatistics, Clinical Sciences +15

Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

David T. Felson, Jennifer J. Anderson, M. Lange et al. · Arthritis & Rheumatism · 1998 · 49 citations

Medicine, Biostatistics, Clinical Sciences +15